All Probiotics are Not the Same in Protecting Premature Infants from Common, Life-Threatening Illness
SACRAMENTO, Calif. (PRWEB) October 17, 2013 -- Treating premature infants with probiotics, the dietary supplements containing live bacteria that many adults take to help maintain their natural intestinal balance, may be effective for preventing a common and life-threatening bowel disease among premature infants, researchers at UC Davis Children’s Hospital have found.
The study, “A comparison of two probiotic strains of bifidobacteria in premature infants,” was recently published online in the Journal of Pediatrics. The bowel disease, necrotizing enterocolitis (NEC), is the second most common cause of death among premature infants, said Mark Underwood, lead study author, neonatologist and professor in the Department of Pediatrics at UC Davis Children’s Hospital. It affects 3 to 10 percent of premature infants; about 25 percent of those with the severe form of NEC succumb to the infection.
Underwood and his collaborators evaluated the effectiveness and safety of two types of probiotics of known purity and composition in a clinical trial that included nine breastmilk- and 12 formula-fed premature infants in the Neonatal Intensive Care Unit (NICU) at UC Davis Children’s Hospital.
The products tested in the study were two genetically different strains of bifidobacteria, normal inhabitants of the gastroentestinal tract that inhibit the growth of harmful pathogens and bacteria: Bifidobacterium longum subspecies infantis (B. infantis) and Bifidobacterium animalis lactis (B. lactis).
Laboratory analysis of bacteria of fecal samples from the infants found that B. infantis was more effective at colonizing bifidobacteria, the healthy bacteria, in the newborns’ gastrointestinal tracts than B.lactis. The highest fecal levels of bifidobacteria were found in the infants who were breastmilk-fed and received the B. infantis probiotic, Underwood said.
No side effects were identified from administration of the two probiotic strains, Underwood said. One of the breastmilk-fed infants treated with B. lactis developed NEC early in the trial, Underwood said, "indicating that B. lactis may not be as effective as B. infantis in protecting against NEC, though the study was not designed to answer that question.”
Because earlier research conducted in Europe, Japan, and Australia has demonstrated the potential benefits of probiotic therapy in preventing NEC, many NICUs in the United States treat premature infants with the supplements, said Underwood. Probiotic therapy is not, however, the standard of care for premature infants in the United States. The American Academy of Pediatrics has not established a policy about using the products in newborns, and the U.S. Food and Drug Administration (FDA) currently regards probiotics as food supplements, not drugs.
The study was conducted in premature infants born between 24 to 33 weeks gestation and weighing less than 1,500 grams, or three pounds. It was conducted in two phases. In the first, the formula-fed infants were randomly assigned to receive either B.infantis or B. lactis in increasing doses over a five-week period. The second phase evaluated the probiotics in breastmilk-fed premature infants. Each infant was treated with one strain for two weeks and, after a one-week break, received the other strain for two weeks.
In both the formula-fed and breast milk-fed newborns, greater increases in fecal bifidobacteria occurred in the B. infantis groups than in the B. lactis groups.
“B. lactis colonization was not sustained in the infants,” Underwood said.
“The highest total numbers and percentages of bifidobacteria were found after two weeks of B. infantis treatment in the breast milk-fed babies,” said Underwood. “In addition, during the one week break in the phase of the study that involved the breast milk-fed infants, the relative abundance of bifidobacteria was significantly greater for those treated with B. infantis.”
During periods of administration of B. infantis, the diversity of the beneficial microbes inhabiting the breast milk-fed babies’ GI tract increased. In addition, the harmful bacteria known as γ-Proteobacteria decreased in the breast milk-fed babies who received B. infantis.
However, the formula-fed infants treated with B. infantis and B. lactis did not experience a decline in the γ-Proteobacteria, which typically increases at the onset of NEC and can cause serious tissue-damaging infections in the gastrointestinal system, lungs and other organs of the body.
The two strains of bifidobacteria used in the study were grown for UC Davis by a food-grade commercial facility to insure that the infants in the study would receive probiotics of known purity and composition, Underwood said.
Specimens were obtained from the stool of the formula-fed infants at baseline, the beginning of the study and then weekly for five weeks. In the breast milk-fed babies, the stool specimens were collected at baseline and following the first probiotic course, the one-week break and the second probiotic course.
Underwood is submitting an application for a new investigational drug to the FDA for a multi-centered second phase clinical trial to evaluate the safety and effectiveness of the B. infantis probiotic in preventing NEC in premature infants. If the application is approved and funded by the National Institutes of Health, Underwood and his colleagues will conduct a larger trial.
The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Development, the National Institute of Allergies and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases grant R01-HD059127 and by the National Center for Advancing Translational Sciences grant UL1 TR000002.
The study’s other authors include Karen M. Kalanetra, Nicholas A. Bokulich, Zachery T. Lewis, Majid Mirmiran, Daniel J. Tancredi and David A. Mills, all of UC Davis.
The UC Davis Clinical and Translational Science Center is part of a national consortium, led by the National Center for Research Resources at the National Institutes of Health, that is improving how biomedical research is conducted across the nation. Its goals are to reduce the time it takes for research discoveries to become treatments for patients, as well as to train the next generation of clinical researchers. For more information, visit http://www.ucdmc.ucdavis.edu/ctsc
UC Davis Children's Hospital is the Sacramento region's only nationally ranked, comprehensive hospital for children, serving infants, children, adolescents and young adults with primary, subspecialty and critical care. It includes the Central Valley's only pediatric emergency department and Level I pediatric trauma center, which offers the highest level of care for critically ill children. The 129-bed children's hospital includes the state-of-the-art 49-bed neonatal and 24-bed pediatric intensive care and pediatric cardiac intensive care units. With more than 120 physicians in 33 subspecialties, UC Davis Children's Hospital has more than 74,000 clinic and hospital visits and 13,000 emergency department visits each year. For more information, visit children.ucdavis.edu.
Phyllis Brown, UC Davis Children's Hospital, 916-734-9023, [email protected]
Share this article